Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/10335
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNikolic V.-
dc.contributor.authorJevtovic Stoimenov, Tatjana-
dc.contributor.authorVeličković-Radovanović R.-
dc.contributor.authorIlic A.-
dc.contributor.authorDeljanin-Ilic M.-
dc.contributor.authorMarinković D.-
dc.contributor.authorApostolovic, Svetlana-
dc.contributor.authorStanojevic D.-
dc.contributor.authorŽivanović, Slavoljub-
dc.contributor.authorStefanović, Nikola-
dc.contributor.authorPesic, Srdjan-
dc.contributor.authorRuzic Zecevic, Dejana-
dc.contributor.authorMilovanovic, Jasmina-
dc.contributor.authorJankovic, Slobodan-
dc.date.accessioned2021-04-20T15:29:28Z-
dc.date.available2021-04-20T15:29:28Z-
dc.date.issued2013-
dc.identifier.issn0031-6970-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/10335-
dc.description.abstractPurpose: The aim of the study was to develop a population pharmacokinetic (PK) model for clearance of bisoprolol in patients with congestive heart failure (CHF). Methods: Parameters associated with the plasma concentrations of bisoprolol at steady-state were analyzed in 61 patients (mean age 66.21 ± 9.49 years; mean total body weight 8.90 ± 12.26 kg) with CHF using non-linear mixed-effect modeling (NONMEM). A validation set of 17 patients with heart failure was used to estimate the predictive performance of the pharmacokinetic model. Results: The typical mean value for bisoprolol clearance (CL), estimated by the base model (without covariates), in our population was 11.4 l h-1. In the full model, covariates such as bisoprolol total daily dose (DD) and creatinine clearance were included. The final regression model for the clearance of bisoprolol was the following: CL (l h-1) = 4.68 + 0.859*DD. Conclusion: The derived PK model describes the clearance of bisoprolol in patients with CHF, showing that the total daily dose of bisoprolol is the most important covariate. This finding will provide the basis for future PK studies on beta blockers in this specific patient population and lead to better overall management of heart failure. © 2012 Springer-Verlag Berlin Heidelberg.-
dc.rightsrestrictedAccess-
dc.sourceEuropean Journal of Clinical Pharmacology-
dc.titlePopulation pharmacokinetics of bisoprolol in patients with chronic heart failure-
dc.typearticle-
dc.identifier.doi10.1007/s00228-012-1427-y-
dc.identifier.scopus2-s2.0-84876705544-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

139

Downloads(s)

9

Files in This Item:
File Description SizeFormat 
PaperMissing.pdf
  Restricted Access
29.86 kBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.